Two patented, complementary technologies: a VHH-based intracellular vectorization platform, and a neuroprotective and neuroregenerative peptide pharmacophore derived from a rabies virus glycoprotein motif. Both arising from academic research carried out at Institut Pasteur.
Two international patent applications, both published on 26 December 2025 and co-owned with Institut Pasteur. They were filed as a deliberate architecture, not as two independent programmes.
An unusual single-domain antibody, engineered to cross two barriers that stop most therapeutics: the blood–brain barrier, and then the plasma membrane of the neuron itself — releasing its cargo into the cytosol rather than trapping it in the endosomal compartment.
A truncated pharmacophore that retains the activity of the parent 42-amino-acid sequence, in a form short enough to be manufactured and fused.
Rabies is among the most lethal pathogens known to medicine — once symptoms appear, survival is almost unheard of. Yet a pathologist examining the brain of a victim finds strikingly little destruction. The neurons are still alive.
The virus has evolved a robust mechanism that forces neurons to survive. It enters at a peripheral wound and reaches the brain by travelling along the nervous system itself, a journey that only succeeds if the neurons it passes through stay alive. So it does the opposite of what its reputation suggests: it actively prevents the cells it infects from dying.
Work led by Monique Lafon — co-founder and Chief Scientific Officer of Neurophoenix — in her laboratory at Institut Pasteur traced that ability to a short motif at the C-terminus of the viral glycoprotein, and to its interaction with MAST2, a host scaffolding protein. The premise of Neurophoenix is to keep the motif and leave the virus behind.
Cell-penetrating peptides such as TAT enter cells efficiently — but they enter through the endosomal pathway. The cargo is taken up into a vesicle, and the great majority of it is degraded there before ever reaching the cytosol.
The cost is not only lost activity. Compensating for what is destroyed means raising the dose, and raising the dose raises toxicity. A delivery route that avoids the endosome therefore improves the therapeutic window, not just the potency.
VHH_NPX is designed for direct cytosolic access, bypassing endocytic uptake rather than trying to escape from it afterwards. In head-to-head comparisons against TAT, the platform showed a 7-fold advantage in vitro and 4.7-fold in vivo.
The lead compound. NPX461 fuses the VHH_NPX domain to the NVshort peptide in a single protein of roughly 15 kDa — small enough to distribute through tissue, large enough to be produced by recombinant expression in bacteria or in mammalian cells. Its antigen-binding loop has been deliberately deactivated, so the antibody scaffold works purely as a vehicle and carries no residual target specificity of its own. It is soluble above 50 mg/mL at physiological pH, and has been measured as high as 130 mg/mL, which leaves ample room for high-concentration formulation; it carries no His-tag.
The same vehicle has been shown to deliver two very different payloads — a therapeutic peptide and an antisense oligonucleotide. That is what makes the platform relevant beyond this single programme.
In a rodent optic nerve crush model, the vectorized fusion protein protected retinal ganglion cells and produced 250–550 µm of axonal regeneration. Activity has been observed in several human cell types.
| Application | Subject | Publication |
|---|---|---|
| WO 2025/262307 A2 | VHH suitable to vectorize molecules intracellularly — platform and lead-product claims | 26 December 2025 |
| WO 2025/262278 A1 | A neurovita short interfering peptide — composition of matter | 26 December 2025 |
Both applications claim priority from 21 June 2024 and are held in equal co-ownership (50/50) with Institut Pasteur. Full texts are available on WIPO Patentscope.
Neurophoenix operates as a focused team. Its two co-founders lead the company, and the scientist behind the original discovery remains its Chief Scientific Officer. The underlying work was carried out in the laboratory of Monique Lafon at Institut Pasteur, which remains co-owner of both patent families.
Neurovirologist, Institut Pasteur. Established the link between the rabies virus glycoprotein motif, MAST2 and neuronal survival that underpins the NVshort pharmacophore.
Responsible for the company's corporate development, intellectual property strategy and partnering.
Supported since inception by